Arvinas names new Chief Medical Officer to advance drug programs By biedexmarkets.com

NEW HAVEN, Conn. – Arvinas, Inc. (NASDAQ:ARVN), a company at the forefront of targeted protein degradation therapeutics, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as its new Chief Medical Officer.

Dr. Berkowitz will also serve on the Executive Committee and report directly to President and CEO John Houston, Ph.D. He takes over the role with immediate effect and will oversee the clinical development of Arvinas’ PROTAC protein degrader programs in oncology and neuroscience.

Dr. Berkowitz brings over two decades of experience to Arvinas, having previously held a leadership position at Bristol-Myers Squibb (NYSE:) as Senior Vice President, Development Unit Head, Hematology. His expertise spans various aspects of clinical development, including trial design and execution.

At Novartis (SIX:), he served as Vice President and Clinical Development Head for Hematology before his tenure at BMS.

The company’s former Chief Medical Officer, Ron Peck, M.D., will be departing to pursue other opportunities. Dr. Peck has been credited with establishing clinical development and medical affairs organizations within Arvinas, as well as advancing the company’s oncology and neuroscience trial programs.

Arvinas has granted Dr. Berkowitz stock options and restricted stock units as part of his employment package. The option to purchase 93,879 shares of common stock and the restricted stock units concerning 63,452 shares were awarded in accordance with Nasdaq Listing Rule 5635(c)(4).

Arvinas is known for its proprietary PROTAC Discovery (NASDAQ:) Engine platform, which is designed to selectively degrade disease-causing proteins. The company’s pipeline includes several clinical-stage programs, such as vepdegestrant for advanced breast cancer and ARV-766 for metastatic castration-resistant prostate cancer, among others.

This announcement is based on a press release statement from Arvinas, Inc. and does not include any independent verification of the claims. The company is on track for its first Phase 3 data readout and is preparing for upcoming clinical milestones with Dr. Berkowitz’s leadership expected to contribute significantly to these efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.